GenKyoTex, PsiOxus Raise VC Funding In Europe To Reach Phase II POC
This article was originally published in The Pink Sheet Daily
Executive Summary
GenKyoTex's first-in-class NOX inhibitors and PsiOxus's oncolytic viruses attract funding from European VCs to cross "death valley."